Community acquired pneumonia.
Copyright policy Community acquired pneumonia.
In the northern hemisphere about 12/1000 people a year (on average) contract pneumonia while living in the community, with most cases caused by Streptococcus pneumoniae. Mortality ranges from about 5% to 35% depending on severity of disease, with a worse prognosis in older people, men, and people with chronic diseases.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent community-acquired pneumonia? What are the effects of treatments for community-acquired pneumonia in outpatient settings, in people admitted to hospital, and in people receiving intensive care? We searched: Medline, Embase, The Cochrane Library, and other important databases up to January 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).We found 15 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.In this systematic review we present information relating to the effectiveness and safety of the following interventions: antibiotics (oral, intravenous), different combinations, and prompt administration of antibiotics in intensive-care settings, early mobilisation, influenza vaccine, and pneumococcal vaccine.
- McMaster University Canada
Adult, Cross Infection, Evidence-Based Medicine, Critical Care, Incidence, Administration, Oral, Pneumonia, Breathing Exercises, Severity of Illness Index, Anti-Bacterial Agents, Hospitalization, Community-Acquired Infections, Pneumococcal Vaccines, Patient Admission, Treatment Outcome, Streptococcus pneumoniae, Influenza Vaccines, Practice Guidelines as Topic, Ambulatory Care, Pneumonia, Bacterial, Humans, Infusions, Intravenous, Early Ambulation, Randomized Controlled Trials as Topic, Aged
Adult, Cross Infection, Evidence-Based Medicine, Critical Care, Incidence, Administration, Oral, Pneumonia, Breathing Exercises, Severity of Illness Index, Anti-Bacterial Agents, Hospitalization, Community-Acquired Infections, Pneumococcal Vaccines, Patient Admission, Treatment Outcome, Streptococcus pneumoniae, Influenza Vaccines, Practice Guidelines as Topic, Ambulatory Care, Pneumonia, Bacterial, Humans, Infusions, Intravenous, Early Ambulation, Randomized Controlled Trials as Topic, Aged
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).7 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!